Biomaterial Database

Treatment of advanced soft tissue and osteogenic sarcomas with continuous infusion of ifosfamide and mesna. 1986

H O Klein, and P Dias Wickramanayake, and C Coerper, and E Christian

UI	MeSH Term	Description	Entries
D007069	Ifosfamide	Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.	Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007262	Infusions, Intravenous	The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.	Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297	Male		Males
D008623	Mercaptoethanol	A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.	2-ME,2-Mercaptoethanol,2 Mercaptoethanol
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012516	Osteosarcoma	A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	Sarcoma, Osteogenic,Osteogenic Sarcoma,Osteosarcoma Tumor,Osteogenic Sarcomas,Osteosarcoma Tumors,Osteosarcomas,Sarcomas, Osteogenic,Tumor, Osteosarcoma,Tumors, Osteosarcoma
D012983	Soft Tissue Neoplasms	Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	Neoplasm, Soft Tissue,Neoplasms, Soft Tissue,Soft Tissue Neoplasm
D015080	Mesna	A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	2-Mercaptoethanesulfonate,Coenzyme M,Ethanesulfonic acid, 2-mercapto-, monosodium salt,ASTA-D 7093,MESNA-cell,Mesnex,Mesnum,Mistabron,Mistabronco,Mitexan,Mucofluid,Sodium 2-Mercaptoethanesulphonate,UCB-3983,Uromitexan,Ziken,2 Mercaptoethanesulfonate,2-Mercaptoethanesulphonate, Sodium,ASTA D 7093,ASTAD 7093,MESNA cell,UCB 3983,UCB3983